In the last years, PD1 axis blockade with pembrolizumab represents the standard of care in this setting of patients as monotherapy or combination according to the tumor PDL-1 expression (defined as Tumor Proportion Score (TPS)). The gene discussed is CD274; the disease is neoplasm.